Home/Filings/4/0000899243-23-007727
4//SEC Filing

Giffin Brett A. 4

Accession 0000899243-23-007727

CIK 0001492674other

Filed

Mar 8, 7:00 PM ET

Accepted

Mar 9, 4:00 PM ET

Size

8.7 KB

Accession

0000899243-23-007727

Insider Transaction Report

Form 4
Period: 2023-02-20
Giffin Brett A.
Chief Commercial Officer
Transactions
  • Sale

    Common Stock

    2023-02-22$0.65/sh537$349841 total
  • Exercise/Conversion

    Common Stock

    2023-02-20+1,3331,378 total
  • Exercise/Conversion

    Restricted Stock Units

    2023-02-201,3332,667 total
    Common Stock (1,333 underlying)
Footnotes (3)
  • [F1]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
  • [F2]The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person adopted by the reporting person on November 10, 2021.
  • [F3]On February 20, 2022 the reporting person was granted 4,000 RSU's that vest in three equal annual installments commencing on February 20, 2023

Issuer

T2 Biosystems, Inc.

CIK 0001492674

Entity typeother

Related Parties

1
  • filerCIK 0001892921

Filing Metadata

Form type
4
Filed
Mar 8, 7:00 PM ET
Accepted
Mar 9, 4:00 PM ET
Size
8.7 KB